Memorial Sloan Kettering Cancer Center

EAP Related Articles from Sponsor

Score contribution: 80 — 8 supporting sources.

Score 808 references

Featured Reference

Expanded Access to L-MTP-PE for the Treatment of OsteosarcomaOpens in new window

This protocol will provide expanded access to treatment with the investigational drug L-MTP-PE for people with osteosarcoma.

Access to Vorasidenib for the Treatment of GliomaSource

This study is providing access to the drug vorasidenib for people with brain cancer. The people in this study have glioma with a mutation (change) in the IDH1 or IDH2 gene.

Access to SNDX-5613 to Treat People with LeukemiaSource

SNDX-5613-0707: Expanded Access Program for SNDX-5613 in Patients with Relapsed/Refractory Acute Leukemias with Genetic Alterations Associated with HOXA Overexpression (EAP)

Access to Belantamab Mafodotin for People with Multiple MyelomaSource

This study offers access to the investigational drug belantamab mafodotin for people with multiple myeloma that has come back or continued to grow despite treatment. It is available for patients who previously received it and benefited from it as well as people with persistent multiple myeloma who have not yet received it.

Following Milestone FDA Approval, MSK Researchers Address Resistance to Larotrectinib through Next-Generation TRK-Targeted TherapeuticSource

Results from a phase I clinical trial and a US Food and Drug Administration expanded access program were presented by David Hyman, MD, the Chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSK), at the American Association for Cancer Research (AACR) Annual Meeting 2019.

Osteosarcoma Clinical TrialsSource

[Expanded Access to L-MTP-PE for the Treatment of Osteosarcoma](https://www.mskcc.org/cancer-care/clinical-trials/20-324)